Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 08:03:27 2024-02-23 am EST 5-day change 1st Jan Change
478.1 DKK +1.12% Intraday chart for Zealand Pharma A/S -1.32% +28.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nordic Shares Rose Monday; Vitrolife Topped Leaders DJ
Zealand Pharma, a new competitor for Novo Nordisk? Our Logo
Weight loss drug windfall attracts pharma companies RE
Drugmakers plot way into obesity market with deals and development RE
Nordic Stocks Decreased Tuesday; TGS Fell Furthest DJ
Zealand Pharma Seeks DKK1.45 Billion from Private Placement MT
Nordic Stocks Dropped Monday; A.P. Moeller-Maersk B Took Biggest Hit Nordic Stocks DJ
Nordic Shares Declined Friday; Yara International Took Biggest Hit DJ
Transcript : Zealand Pharma A/S Presents at Goldman Sachs Healthcare C-Suite Unscripted Conference, Jan-04-2024 10:10 AM
US FDA Identifies Deficiencies at Manufacturing Plant for Zealand Pharma's Hypoglycemia Drug MT
Zealand says US FDA turns down drug for low blood sugar in infants RE
Zealand Pharma Files New Drug Application for Bowel Syndrome Therapy with US FDA MT
Zealand Pharma Secures EUR90 Million Loan Facility MT
Nordic Stocks Moved Upward Wednesday; Jeudan Climbed Highest DJ
Transcript : Zealand Pharma A/S - Special Call
Roche enters obesity drugs race with $2.7 bln Carmot deal RE
Roche enters obesity drugs race with $2.7 bln Carmot deal RE
Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers CI
Nordic Shares Closed Up Wednesday; ALK-Abello Series B Led Increases DJ
Transcript : Zealand Pharma A/S, Q3 2023 Earnings Call, Nov 09, 2023
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nordic Stocks Moved Upward Monday; Filo Topped Leaders DJ
Nordic Stocks Rose Tuesday; NEL Led Increases DJ
Zealand Pharma, Boehringer Ingelheim Begin Phase 3 Trials for Obesity Drug Candidate Survodutide MT
Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials CI
Chart Zealand Pharma A/S
More charts
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
472.8 DKK
Average target price
459.2 DKK
Spread / Average Target
-2.88%
Consensus
1st Jan change Capi.
+28.19% 4 262 M $
+4.87% 110 B $
+9.77% 104 B $
+9.14% 23 902 M $
-11.35% 22 243 M $
-25.63% 21 573 M $
-7.10% 18 925 M $
-14.74% 16 036 M $
+1.24% 13 271 M $
+39.77% 12 608 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
  4. News Zealand Pharma A/S
  5. Zealand Pharma Says FDA Granted Priority Review Designation for Dasiglucagon in Congenital Hyperinsulinism
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer